I-07 Anders Kristoffersson Optimal design of in vitro time kill curve experiments for the evaluation of antibiotic effects. Wednesday 10:15-11:45 |
I-08 Claus Andersen Trial Sample Size Estimation and Study Design Assessment using Monte Carlo Sampling Wednesday 10:15-11:45 |
I-12 Caroline Bazzoli New features for population design evaluation and optimisation with R functions: PFIM Interface 3.1 and PFIM 3.2 Wednesday 10:15-11:45 |
I-34 Núria Buil Bruna The feasibility of model-based exposure calculations in preclinical toxicology Wednesday 10:15-11:45 |
II-04 Anne Dubois Evaluation of designs for biosimilarity crossover trials analysed by nonlinear mixed effects models Wednesday 14:55-16:10 |
II-06 Cyrielle Dumont Design evaluation in nonlinear mixed effect models: influence of covariance between random effects Wednesday 14:55-16:10 |
II-12 Karl-Heinz Liesenfeld Modeling and simulation to optimise the study design investigating the hemodialysis of dabigatran in patients with end stage renal disease (ESRD) Wednesday 14:55-16:10 |
II-30 Gordon Graham An Application of Optimal Design to Dose Selection and Sample Size Determination with a Negative-Binomial Exposure-Response Model for a Phase IIb Study Wednesday 14:55-16:10 |
II-54 Matts Kågedal Improved study design in phase IIb by the use of optimal design, focusing on the precision of dose finding Wednesday 14:55-16:10 |
III-24 France Mentré Comparison of results of the different software for design evaluation in population pharmacokinetics and pharmacodynamics Thursday 09:50-11:05 |
III-32 Thu Thuy Nguyen Evaluation of Fisher information matrix using Gaussian quadrature in nonlinear mixed effects models: application to dose-response trials Thursday 09:50-11:05 |
III-33 Thu Thuy Nguyen Designing a dose-response study analysed by nonlinear mixed effects models Thursday 09:50-11:05 |
III-38 Joakim Nyberg Parallelization in optimal experimental design using PopED Thursday 09:50-11:05 |
III-39 Joakim Nyberg Population optimal design with correlation using Markov Models Thursday 09:50-11:05 |
III-59 Italo Poggesi Efficiency criteria generated by optimal design tools should be evaluated in the light of study objectives Thursday 09:50-11:05 |
III-64 Elba Romero PK/PD sampling design optimization following a sustained release formulation of triptorelin using optimal experimental design Thursday 09:50-11:05 |
IV-20 Amit Taneja Optimisation of Screening Experiments for the Assessment of Analgesic Effects Thursday 15:05-16:20 |
IV-24 Donato Teutonico Multivariate patient simulation for clinical trial optimization in COPD Thursday 15:05-16:20 |
IV-43 Camille Vong Optimal Design of Anticancer Regimens Thursday 15:05-16:20 |
IV-56 Shuying Yang Using Placebo FEV1 Response to Improve the efficiency of clinical trials in Asthma Thursday 15:05-16:20 |